current value, page-13

POH is about 3 years in front of MBP with their transdermal technology and already have phase I data with insulin. Lots of other companies out there with technology that could work orally or transdermally for drug delivery. MBP are 18 months (read > 2 years) from doing a human trial with their (alleged) oral delivery platform which is just a fancy name for smoke and mirrors – they’ve got jack – just like their fat pill results and now ACV1 results which they don’t even have the guts to release to shareholders, instead just blaming someone else’s in vitro rat study for why they are terminating it. Year 10 science students could run and report on clinical trials than these f*wits.